news
Coherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
List view / Grid view
Biologics
news
New painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
news
NKTR-255 shows positive results in lymphoma therapy
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
news
Refeyn launches software platform to automate mass photometry workflows
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
article
Toxicology transformed: Why accuracy now leads the way
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
article
Women pioneering change in biotech and protein production
Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.
article
New insights into the role of viral capsids in gene therapy safety
Viral capsid assembly and quality are key factors in gene therapy success and safety. Here, Dr Chelsea Pratt explores how cutting-edge tools are enabling scientists to tackle these challenges and improve patient outcomes.
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
article
Unlocking a new molecular space in rapid drug discovery
So-called undruggable pharmaceutical targets could be tackled with intermediate sized drugs such as macrocycles, combining the advantages of small molecules and biologics. The preparation of very large libraries of chemically synthesised intermediate-sized molecules is now in reach with a new technology developed at ETH Zurich. In this article, Dr Michelle…
article
Unlocking the potential of smart antibodies
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment.…
webinar
Advancing therapeutics targeting cytokines with functional cell-based assays
3 January 2024 | By Eurofins DiscoverX
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
webinar
Functional assays for the development of agonistic antibodies
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
article
Condensate biology: advancing drug discovery for complex diseases
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
video
Video: Four integrated technologies for biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.
webinar
Validated bioassays for metabolic & gastrointestinal diseases: Accelerating development of GLP-1 & -2 therapeutics
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.